Analytical Tool - Protein Kinase Inhibitors in Oncology" offers a unique tool for analyzing the vast amount of strategic possibilities that have emerged in the drug development of protein kinase inhibitors (PKIs) for the treatment of cancer. It is at the same time a map of the research and development, a history of the achievements up to date, and a guide pointing out the directions of the future. The product as well, lays the framework of current treatment strategies and their progress. This tool provides you with an immense amount of information structured and analyzed to assist you in your work. It is designed to assist you in finding right partners, optimizing your licensing deals, wisely choosing which projects give you the best competitive advantage, and assuring you that your decisions have been based on the most accurate, validated and precise facts available.

Included in this advantageous package are two products already appreciated by many of our customers:

Competitive Insights to Protein Kinase Therapeutics in Oncology: The Faster Route to Consider Your Options and Position of Others
Protein Kinase Inhibitors in Oncology: Drug Pipeline Update 2014*

The Package Includes
* A progress analysis on current and emerging drugs
* Information on most companies active in the development of PKIs in oncology
* Information on key industry related PKI drug projects in oncology
* Data from most important clinical trials
* Information on early developmental stage projects
* Possibility of performing advanced searches suited to your individual needs

This Tool will Assist You in:
* Tracking cutting edge companies, therapies and new technologies
* Rapid identification of partners & competitors
* Laying down a comprehensive framework for further analysis of the field
* Producing presentations surrounding the development of PKI drugs in oncology
* Identifying emerging PKI cancer products & key areas of pharmaceutical R&D

*This software application is a searchable database reflects the most recent advances in the field of PKI drug development in cancer, in order to help you perform your own analysis, go back to the source data for in-depth information, and present the research and development in tables and graphs suited for your own specific purposes. A significant advantage with BioSeeker's software applications is that they provide you with well-structured information. Each pipeline drug/project has been carefully defined and classified in categories and subcategories. The main categories include therapy type, effect, mechanism of action (molecular target), indication, stage of development etc. These categories are further organized and classified in sub-categories. In comparison with other available databases, BioSeeker’s software applications give better overview, specific search capabilities and great dynamic reports.

Table Of Contents

Analytical Tool - Protein Kinase Inhibitors in Oncology

View This Report »

Find all the market research you need - instantly, in one place.

+1.2 Million Research Documents & Statistics +200,000 Trusted Public Sources 350 Industries With Global Coverage

24/7 Customer Support

Talk to Louis

+1 718 618 4302

Purchase Reports From Reputable Market Research Publishers

Oncology Partnering Terms and Agreements

Oncology Partnering Terms and Agreements

  • $ 2 995
  • Industry report
  • December 2014
  • by Currentpartnering

The Oncology Partnering Terms and Agreements report provides comprehensive understanding and unprecedented access to the oncology/cancer partnering deals and agreements entered into by the worlds leading ...

Bile Duct Cancer (Cholangiocarcinoma) Global Clinical Trials Review, H1, 2015

Bile Duct Cancer (Cholangiocarcinoma) Global Clinical Trials Review, H1, 2015

  • $ 2 500
  • Industry report
  • February 2015
  • by Global Data

Bile Duct Cancer (Cholangiocarcinoma) Global Clinical Trials Review, H1, 2015 Summary GlobalData's clinical trial report, “Bile Duct Cancer (Cholangiocarcinoma) Global Clinical Trials Review, H1, 2015" ...

Chemotherapy Induced Peripheral Neuropathy - Pipeline Review, H2 2014

Chemotherapy Induced Peripheral Neuropathy - Pipeline Review, H2 2014

  • $ 2 000
  • Industry report
  • December 2014
  • by Global Markets Direct

Chemotherapy Induced Peripheral Neuropathy - Pipeline Review, H2 2014 Summary Global Markets Direct’s, ‘Chemotherapy Induced Peripheral Neuropathy - Pipeline Review, H2 2014’, provides an overview ...


Download Unlimited Documents from Trusted Public Sources

Oncology Market Trends - Forecast

  • February 2015
    2 pages
  • Oncology  

    Cancer  

    Radiation Thera...  

View report >

Oncology Industry in the UK

  • February 2015
    24 pages
  • Oncology  

    Cancer Therapy  

  • United Kingdom  

View report >

Cancer Drug Industry in the UK

  • January 2015
    4 pages
  • Cancer Drug  

    Cancer  

    Oncology  

  • United Kingdom  

    World  

    Europe  

View report >

ReportLinker is an award-winning market research solution that finds, filters and organizes the latest industry data so you get all the market research you need - quickly, in one place.